Nurr1 and Foxa2 Delivered by Adeno‐Associated Virus 9 Ameliorate the Pathologies and Symptoms of Alzheimer’s Disease Models

Since conventional chemical drugs or proteins have not shown sufficient clinical benefits for cognitive impairments in Alzheimer’s disease (AD), we could try to develop novel therapeutic interventions for AD such as gene therapy. In this study, we evaluated a novel therapeutic modality of AAV9 vectors expressing Nurr1 and Foxa2 genes to treat AD symptoms and pathologies in animal disease models.